These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 19573588

  • 41. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
    Zaugg K, Rocha S, Resch H, Hegyi I, Oehler C, Glanzmann C, Fabbro D, Bodis S, Pruschy M.
    Cancer Res; 2001 Jan 15; 61(2):732-8. PubMed ID: 11212276
    [Abstract] [Full Text] [Related]

  • 42. α1-Adrenergic drugs modulate differentiation and cell death of human erythroleukemia cells through non adrenergic mechanism.
    Fuchs R, Schraml E, Leitinger G, Stelzer I, Allard N, Haas HS, Schauenstein K, Sadjak A.
    Exp Cell Res; 2011 Oct 01; 317(16):2239-51. PubMed ID: 21781962
    [Abstract] [Full Text] [Related]

  • 43. AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia.
    Eriksson A, Kalushkova A, Jarvius M, Hilhorst R, Rickardson L, Kultima HG, de Wijn R, Hovestad L, Fryknäs M, Öberg F, Larsson R, Parrow V, Höglund M.
    Biochem Pharmacol; 2014 Jan 15; 87(2):284-91. PubMed ID: 24200998
    [Abstract] [Full Text] [Related]

  • 44. Stathmin expression and megakaryocyte differentiation: a potential role in polyploidy.
    Rubin CI, French DL, Atweh GF.
    Exp Hematol; 2003 May 15; 31(5):389-97. PubMed ID: 12763137
    [Abstract] [Full Text] [Related]

  • 45. Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia.
    Zhang L, Zhao H, Sun A, Lu S, Liu B, Tang F, Feng Y, Zhao L, Yang R, Han ZC.
    Haematologica; 2004 Oct 15; 89(10):1199-206. PubMed ID: 15477204
    [Abstract] [Full Text] [Related]

  • 46. Autocrine signaling of platelet-derived growth factor regulates disabled-2 expression during megakaryocytic differentiation of K562 cells.
    Tseng CP, Chang P, Huang CL, Cheng JC, Chang SS.
    FEBS Lett; 2005 Aug 15; 579(20):4395-401. PubMed ID: 16061224
    [Abstract] [Full Text] [Related]

  • 47. Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug.
    He H, Tran P, Gu H, Tedesco V, Zhang J, Lin W, Gatlik E, Klein K, Heimbach T.
    Drug Metab Dispos; 2017 May 15; 45(5):540-555. PubMed ID: 28270565
    [Abstract] [Full Text] [Related]

  • 48. Phytosphingosine promotes megakaryocytic differentiation of myeloid leukemia cells.
    Han SH, Kim J, Her Y, Seong I, Park S, Bhattarai D, Jin G, Lee K, Chung G, Hwang S, Bae YS, Kim J.
    BMB Rep; 2015 Dec 15; 48(12):691-5. PubMed ID: 26077028
    [Abstract] [Full Text] [Related]

  • 49. Midostaurin administration in two hemodialysis patients.
    Tollkuci E, Seddon A, Geswein L, Mulseh M.
    J Oncol Pharm Pract; 2019 Jul 15; 25(5):1285-1288. PubMed ID: 30253726
    [Abstract] [Full Text] [Related]

  • 50. Induction of differentiation and apoptosis in three human leukemia cell lines by a new compound from Dendrostellera lessertii.
    Yazdanparast R, Mahdavi M, Moosavi MA.
    Acta Biochim Biophys Sin (Shanghai); 2006 Jul 15; 38(7):477-83. PubMed ID: 16820863
    [Abstract] [Full Text] [Related]

  • 51. A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects.
    Yin OQ, Wang Y, Schran H.
    Clin Pharmacokinet; 2008 Jul 15; 47(12):807-16. PubMed ID: 19026036
    [Abstract] [Full Text] [Related]

  • 52. Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics.
    Mirza Z, Schulten HJ, Farsi HM, Al-Maghrabi JA, Gari MA, Chaudhary AG, Abuzenadah AM, Al-Qahtani MH, Karim S.
    PLoS One; 2015 Jul 15; 10(3):e0119765. PubMed ID: 25789858
    [Abstract] [Full Text] [Related]

  • 53. Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus.
    Wang Y, Yin OQ, Graf P, Kisicki JC, Schran H.
    J Clin Pharmacol; 2008 Jun 15; 48(6):763-75. PubMed ID: 18508951
    [Abstract] [Full Text] [Related]

  • 54. Midostaurin and cyclosporine drug interaction: A case report.
    Mancini R, LaMontagne L, Williams T, Kreisle W, Petersen F.
    J Clin Pharm Ther; 2020 Apr 15; 45(2):384-387. PubMed ID: 31782821
    [Abstract] [Full Text] [Related]

  • 55. A natural-like synthetic small molecule impairs bcr-abl signaling cascades and induces megakaryocyte differentiation in erythroleukemia cells.
    Turroni S, Tolomeo M, Mamone G, Picariello G, Giacomini E, Brigidi P, Roberti M, Grimaudo S, Pipitone RM, Di Cristina A, Recanatini M.
    PLoS One; 2013 Apr 15; 8(2):e57650. PubMed ID: 23460890
    [Abstract] [Full Text] [Related]

  • 56. A Carbon 21 Steroidal Glycoside with Pregnane Skeleton from Cynanchum atratum Bunge Promotes Megakaryocytic and Erythroid Differentiation in Erythroleukemia HEL Cells through Regulating Platelet-Derived Growth Factor Receptor Beta and JAK2/STAT3 Pathway.
    Yang J, Pan C, Pan Y, Hu A, Zhao P, Chen M, Song H, Li Y, Hao X.
    Pharmaceuticals (Basel); 2024 May 14; 17(5):. PubMed ID: 38794198
    [Abstract] [Full Text] [Related]

  • 57. Mast cell leukemia with prolonged survival on PKC412/midostaurin.
    Xu X, Kreisel FH, Frater JL, Hassan A.
    Int J Clin Exp Pathol; 2014 May 14; 7(6):3439-43. PubMed ID: 25031773
    [Abstract] [Full Text] [Related]

  • 58. Midostaurin Modulates Tumor Microenvironment and Enhances Efficacy of Anti-PD-1 against Colon Cancer.
    Lai CT, Chi CW, Wu SH, Shieh HR, Yen JC, Chen YJ.
    Cancers (Basel); 2022 Oct 04; 14(19):. PubMed ID: 36230769
    [Abstract] [Full Text] [Related]

  • 59. Cinnamon effectively inhibits the activity of leukemia stem cells.
    Guan X, Su MC, Zhao RB, Ouyang HM, Dong XD, Hu P, Pei Q, Lu J, Li ZF, Zhang CR, Yang TH.
    Genet Mol Res; 2016 Aug 19; 15(3):. PubMed ID: 27706567
    [Abstract] [Full Text] [Related]

  • 60. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study.
    Millward MJ, House C, Bowtell D, Webster L, Olver IN, Gore M, Copeman M, Lynch K, Yap A, Wang Y, Cohen PS, Zalcberg J.
    Br J Cancer; 2006 Oct 09; 95(7):829-34. PubMed ID: 16969355
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.